OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (TPex ticker: 4174). OBI’s mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo Series (incl. Globo H, SSEA3, SSEA4), AKR1C3 and Trop-2. Globo Series and AKR1C3 are highly expressed in cancers of unmet need including Breast, Ovarian, Gastric, Lung, Liver, Prostate and Esophageal. The company’s innovative oncology portfolio includes:
● Adagloxad Simolenin (Globo H cancer vaccine)
● OBI-833 (Globo H cancer vaccine)
● OBI-999 (Globo H ADC)
● OBI-3424 (small-molecule prodrug targeting AKR1C3 enzyme)
● R-992 (Trop-2 ADC)
OBI is looking for partners to license or co-develop to maximize the development potential of our products.